iVoice's Subsidiary Thomas Pharmaceuticals Featured in Leading Publication For Supermarket Industry
Business Wire "US Press Releases "
MATAWAN, N.J.--(BUSINESS WIRE)--
Thomas Pharmaceuticals Ltd ("Thomas Pharmaceuticals"), a wholly owned subsidiary of iVoice, Inc. (OTCBB:IVOI), announced today that its new upscale antacid tablet product line Acid + All(TM) is featured in an editorial in Supermarket News, a leading magazine covering activities, news and issues impacting the supermarket industry. The article highlights the potential for Acid+All, citing the product's creative packaging as on-target for baby boomers. Recently, Thomas Pharmaceuticals announced that more than 20,000 drug stores chains were carrying the product line.
Acid + All(TM), the calcium enriched, spearmint-flavored, sugar free tablets that soothe heartburn, acid indigestion and gas is available at independent pharmacies, major drug chains and online retailers or by calling toll-free at 1-888-922-1959. Acid + All(TM) will be available in a sleek, 32-count pillbox and will retail for approximately $3.89. Thomas Pharmaceuticals plans to introduce Acid + All(TM) line extensions later this year along with other new over-the-counter products. For more information about Acid + All(TM) go to www.acidall.com.
Thomas Pharmaceuticals Ltd., based in New York, N.Y., develops and markets over the counter non-prescription healthcare products. The company focuses on high-end, branded consumables. Its first product, Acid + All(TM), is a calcium-enriched, sugar free, anti-gas antacid. On August 9, 2006, iVoice, Inc. entered into a Stock Purchase Agreement dated August 7, 2006 by and among Thomas Pharmaceuticals Ltd.,Thomas Pharmaceutical Acquisition Corp. ("Thomas Acquisition") and iVoice, Inc. whereby Thomas Acquisition has agreed to purchase all of the outstanding securities presently held by iVoice. iVoice may terminate this Stock Purchase Agreement should the closing not have occurred by October 31, 2006. Thomas Acquisition is substantially controlled by the original founders and management of Thomas Pharmaceuticals.
About iVoice, Inc:
iVoice has determined that the best way to create shareholder value, separate and apart from the operating performance of iVoice, is to implement new business opportunities by distributing shares of spin-offs to the company's shareholders. The common stock distributions are part of a broader strategy relating to the transition of iVoice into a company focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may make financing more appealing to potential investors.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
iVoice Subsidiary's Acid + All(TM) Named One of Top 10 New Products By Leading Drug Store Publication
Business Wire "US Press Releases "
MATAWAN, N.J.--(BUSINESS WIRE)--
Thomas Pharmaceuticals Ltd ("Thomas Pharmaceuticals"), a wholly owned subsidiary of iVoice, Inc. (OTCBB:IVOI), announced today that its new upscale antacid tablet product line Acid + All(TM) was named one of the top 10 new products by editors of Drug Store News, a leading publication focused on the drug store industry. The publication evaluated numerous new products and selected Acid + All(TM) as one of the top 10. Recently, Thomas Pharmaceuticals announced that more than 20,000 drug stores chains were carrying the product line.
"We are pleased that a leading industry publication has recognized what consumers are increasingly recognizing, that Acid + All is one of the most promising products to be issued in many years," said Tom Thomas, President and Founder of Thomas Pharmaceuticals. "Increasingly, leading retailers and drug store chains are responding to consumer demand by offering the product."
Acid + All(TM), the calcium enriched, spearmint-flavored, sugar free tablets that soothe heartburn, acid indigestion and gas is available at independent pharmacies, major drug chains and online retailers or by calling toll-free at 1-888-922-1959. Acid + All(TM) will be available in a sleek, 32-count pillbox and will retail for approximately $3.89. Thomas Pharmaceuticals plans to introduce Acid + All(TM) line extensions later this year along with other new over-the-counter products. For more information about Acid + All(TM) go to www.acidall.com.
About Thomas Pharmaceuticals
Thomas Pharmaceuticals Ltd., based in New York, N.Y., develops and markets over the counter non-prescription healthcare products. The company focuses on high-end, branded consumables. Its first product, Acid + All(TM), is a calcium-enriched, sugar free, anti-gas antacid. On August 9, 2006, iVoice, Inc. entered into a Stock Purchase Agreement dated August 7, 2006 by and among Thomas Pharmaceuticals Ltd.,Thomas Pharmaceutical Acquisition Corp. ("Thomas Acquisition") and iVoice, Inc. whereby Thomas Acquisition has agreed to purchase all of the outstanding securities presently held by iVoice. iVoice may terminate this Stock Purchase Agreement should the closing not have occurred by October 31, 2006. Thomas Acquisition is substantially controlled by the original founders and management of Thomas Pharmaceuticals.
About iVoice, Inc:
iVoice has determined that the best way to create shareholder value, separate and apart from the operating performance of iVoice, is to implement new business opportunities by distributing shares of spin-offs to the company's shareholders. The common stock distributions are part of a broader strategy relating to the transition of iVoice into a company focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may make financing more appealing to potential investors.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
iVoice's Thomas Pharmaceuticals Ltd. Announced Acid + All(TM) Antacid Table Product Line Now in More Than 20,000 Drug Stores Nationwide
Business Wire "US Press Releases "
MATAWAN, N.J.--(BUSINESS WIRE)--
Thomas Pharmaceuticals Ltd ("Thomas Pharmaceuticals"), a wholly owned subsidiary of iVoice, Inc. (OTCBB:IVOI), announced today that its new upscale antacid tablet product line Acid + All(TM) is now in more than 20,000 pharmacies and drug stores since the launch of the product line approximately six months ago. The stores include leading drugstore chains, such as Rite Aid Corporation which recently reordered the product due to the success of its initial order.
"We are pleased that in a short period of time that Acid + All(TM) has enjoyed such success from leading drugstore chains and pharmacies across the country that more than 20,000 of them have elected to carry the product," said Tom Thomas, President and Founder of Thomas Pharmaceuticals. "Despite the rapid adoption of the product, in the coming months we plan to further increase distribution by expanding relationships with drugstore chains such as Rite Aid Corporation and other leading retailers."
Acid + All(TM), the calcium enriched, spearmint-flavored, sugar free tablets that soothe heartburn, acid indigestion and gas is available at independent pharmacies, major drug chains and online retailers or by calling toll-free at 1-888-922-1959. Acid + All(TM) will be available in a sleek, 32-count pillbox and will retail for approximately $3.89. Thomas Pharmaceuticals plans to introduce Acid + All(TM) line extensions later this year along with other new over-the-counter products. For more information about Acid + All(TM) go to www.acidall.com.
About Thomas Pharmaceuticals
Thomas Pharmaceuticals Ltd., based in New York, N.Y., develops and markets over the counter non-prescription healthcare products. The company focuses on high-end, branded consumables. Its first product, Acid + All(TM), is a calcium-enriched, sugar free, anti-gas antacid. On August 9, 2006, iVoice, Inc. entered into a Stock Purchase Agreement dated August 7, 2006 by and among Thomas Pharmaceuticals Ltd.,Thomas Pharmaceutical Acquisition Corp. ("Thomas Acquisition") and iVoice, Inc. whereby Thomas Acquisition has agreed to purchase all of the outstanding securities presently held by iVoice. iVoice may terminate this Stock Purchase Agreement should the closing not have ocurred by October 31, 2006. Thomas Acquisition is substantially controlled by the original founders and management of Thomas Pharmaceuticals.
About iVoice, Inc:
iVoice has determined that the best way to create shareholder value, separate and apart from the operating performance of iVoice, is to implement new business opportunities by distributing shares of spin-offs to the company's shareholders. The common stock distributions are part of a broader strategy relating to the transition of iVoice into a company focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may make financing more appealing to potential investors.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
posted
Trey Resources Closes Transaction with Prestigious New York City Hotel Operator
LIVINGSTON, N.J., July 24, 2007 /PRNewswire-FirstCall via COMTEX/ -- Trey Resources, Inc. (OTC Bulletin Board: TYRIA) announced today that the company's wholly owned subsidiary, SWK Technologies, Inc., the premier total solutions provider specializing in business software for manufacturers and distributors, has closed on a significant software sale with one of the preeminent hotel owner/operators in New York City. The transaction, which involved Sage Software's MAS 500 and attendant services, was valued at roughly $38,000.
Jeffrey D. Roth, CEO of SWK Technologies, said, "Sales continue to close at a record pace. We previously announced that we expect more new MAS 500 transactions, and we have lived up to that commitment. Our company's growing reputation for depth of talent, quality, and service has placed us in the enviable position of quoting on a series of very large opportunities. Our sales momentum continues at a record pace, and we look forward to announcing even more exciting deals in the very near future."
About Trey Resources
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
iVoice, Inc., Announces Record Date for Spin-Off of Thomas Pharmaceuticals Ltd. To Shareholders 3:31 PM EST November 8, 2007 MATAWAN, N.J.--(BUSINESS WIRE)--
iVoice, Inc. (OTC Bulletin Board: IVOI), announced today the record date of November 14, 2007 for the pending spin-off in the form of a special dividend of its wholly owned subsidiary, Thomas Pharmaceuticals Ltd. ("Thomas Pharmaceuticals").
Each iVoice shareholder of record as of November 14 2007 will receive shares of Thomas Pharmaceuticals. In order to receive shares in Thomas Pharmaceuticals, you must own shares of iVoice, Inc. on the record date of November 14, 2007. It is anticipated that the distribution in the form of a special dividend of Thomas Pharmaceuticals shares will occur sometime in November 2007. Following the distribution, Thomas Pharmaceuticals plans to have its shares traded on the NASD OTC Bulletin Board. Each holder of iVoice Class A Common Stock, except for certain affiliates, will receive one share of Thomas Pharmaceuticals, Ltd. Class A Common Stock for each share of iVoice Class A Common Stock held.
The Company revised the record date for the distribution of the Thomas Pharmaceuticals spin-off to November 14, 2007 to permit the Company to register additional shares with the Securities and Exchange Commission to reflect the recent increase in the number of outstanding shares of iVoice as a result of a conversion by a holder of an outstanding convertible debenture to Class A Common Stock of iVoice.
About iVoice, Inc:
iVoice has determined that the best way to create shareholder value, separate and apart from the operating performance of iVoice, is to implement new business opportunities by distributing shares of spin-offs to the Company's shareholders. The common stock distributions are part of a broader strategy relating to the transition of iVoice into a company focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may make financing more appealing to potential investors.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
posted
Guess I am the only one here who made out like a bandit?
-------------------- Please DON'T invest on JMO. Do YOUR research. Invest UR money the way YOU would like to! Thanks! ;) Posts: 936 | From: Virginia | Registered: Aug 2007
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
